本帖最后由 老马 于 2013-3-13 13:43 编辑 . y8 U9 `' L8 R( S D/ c
. }- h, |, x' b/ O
健择（吉西他滨）+顺铂+阿瓦斯汀
" Z9 |3 V+ ]& o" z( x/ Y Gemzar +Cisplatin + Avastin
1 L7 |* `& B2 [4 o. _7 Ihttp://annonc.oxfordjournals.org/content/21/9/1804.full- f+ u. h5 R$ I+ z8 {
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% | i$ u+ o7 ?) s; JPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 5 M Z" N% v" @3 s* D! B& ?
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. Q; `4 k& y" W) A4 |
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 321)
" A- s/ Q8 m( U! q( o; {7 s/ S0 H华为网盘附件：- t1 x# m0 A; a. g, P
【华为网盘】ava.JPG
/ q" o3 }3 K5 o |
显身卡
